Dorte X. Gram
Several triggers for Pila Pharma in 2022
There is no doubt that type 2 diabetes has become one of the most common diseases with more than a...
CEO increases holding in Pila Pharma
When Malmö-based Pila Pharma was admitted to trading...
Pila Pharma rounds off the first quarter as a listed company
2021 has so far been a composing year in...
Pila Pharma takes final steps before toxicological studies
After the summer's IPO, there is full activity in...
BioStock Studio: Pila Pharma's CEO about the company and the IPO
Malmö company Pila Pharma is developing the drug candidate XEN-D0501 for the treatment...
Pila Pharma wants to take a new approach to diabetes
No one has escaped the fact that diabetes has spread...
Diabetes veteran on the listing of Pila Pharma
Pila Pharma is developing the drug candidate XEN-D0501, aiming to...
CEO interview Pila Pharma: »If I'm right, this could be gigantic«
Pila Pharma was able to announce the other day that it had passed...
Notes
Mentice consolidates operations to Denver
Bio-Works secures million-dollar order from global pharmaceutical company
OncoZenge receives investment proceeds from Yangtian Bio-Pharmaceutical
Xspray Pharma confirms bioequivalence for XS003
Evaxion converts debt of EUR 3,5 million
NEWSLETTER
NEWS
AI-designed proteins are created in seconds
The price of Leqembi needs to be lowered in Japan
Merck gears up in lung diseases with giant acquisition
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
